Fig. 10: Vaccination with Pam2Cys Spike induces potent sustained protection against SARS-CoV-2 challenge. | Nature Communications

Fig. 10: Vaccination with Pam2Cys Spike induces potent sustained protection against SARS-CoV-2 challenge.

From: Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Fig. 10

K18-hACE2 mice (n = 5) were immunized with Pam2Cys alone (P2C; black), or Pam2Cys Spike, sub-cutaneously (s.c; blue) or intra-nasally (i.n; red) three times, 2.5 weeks apart. 6 weeks post final vaccination mice were challenged with SARS-CoV-2 i.n. a Anti-spike IgG and IgA titres in serum collected 5 weeks post final vaccination, as determined by ELISA. b Mouse weight loss from days 0–6 post infection (p.i) with SARS-CoV-2. c Clinical score distribution, increasing category indicates severity, (no clinical score, green; category 1, yellow; category 2, orange; category 3, red) (d) viral load (plaque forming units; PFU) at day 6 p.i. Limits of detection (LOD) indicated by the dotted lines. Data are for individual mice (n = 5 each), means + /− SEM are shown. Statistics: (a) Welch’s t test, (b) Two-way ANOVA with Tukey’s multiple comparisons, (d) Kruskal–Wallis test, Dunn’s multiple comparisons. p-values are indicated. Source data are provided as a Source Data file.

Back to article page